Viewing Study NCT05758116


Ignite Creation Date: 2025-12-26 @ 11:47 AM
Ignite Modification Date: 2025-12-26 @ 11:47 AM
Study NCT ID: NCT05758116
Status: RECRUITING
Last Update Posted: 2024-11-26
First Post: 2023-02-17
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Sponsor: Peking University Cancer Hospital & Institute
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module